Targeted ferritin ferroptosis induced nano dosage form as well as preparation method and application thereof

By designing a ferritin-induced nanodosage form targeting ferritin, targeting ferritin and iron in the prior art is solved by using the PROTAC molecule of polyunsaturated fatty acids and E3 ubiquitin ligase ligands to bind to MOF-Fe nanoparticles. The problem of low efficiency of death inducers has achieved breakthroughs in efficient killing of tumor cells and apoptosis-resistant cells.

CN118892496AActive Publication Date: 2024-11-05HUAZHONG UNIV OF SCI & TECH
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202410930426.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-11
Publication Date
2024-11-05
Estimated Expiration
2044-07-11

Smart Images

  • Figure CN118892496A_ABST
    Figure CN118892496A_ABST
Patent Text Reader

Abstract

The invention designs a ferritin-targeted ferroptosis induced nano dosage form based on PROTAC design, the structural general formula of the ferritin-targeted ferroptosis induced nano dosage form is as shown in I: # imgabs0 #, # imgabs1 # represents a ligand of E3 ubiquitin ligase,-L-represents a linking group and is selected from an unsubstituted C1-50 alkyl chain or a C1-50 alkyl chain optionally containing one or more heteroatoms, and the heteroatoms can be selected from O, S and N; and # imgabs2 # represents various saturated or unsaturated long alkyl chains. Aiming at ferritin without a commercial inhibitor, the ferritin can degrade target protein in cells at a relatively low concentration, and cooperates with an iron-based metal organic framework to induce iron ion overload and induce Fenton reaction to generate reactive oxygen species (ROS), so that accumulation of lipid peroxidation is caused, and cell ferroptosis is induced. It is further verified that the compound has good degradation activity and tumor killing effect in pancreatic cancer, and has high safety and wide application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical field:

[0001] The present invention relates to the field of biomedicine technology, and in particular to a ferroptosis-inducing nano dosage form targeting ferritin, and a preparation method and application thereof. Background technology:

[0002] Tumor is one of the important diseases that affect human health and has become the second leading cause of death in the world. Tumor treatment mainly includes traditional surgical treatment, radiotherapy, chemotherapy and new treatment methods such as targeted therapy and immunotherapy that have developed rapidly in recent years. Because tumors have the characteristics of continuous replenishment of growth-promoting signals; extensive inhibition of anti-growth signals; resistance to cell death; unlimited replication ability; continuous angiogenesis; tissue infiltration and metastasis; avoidance of immune destruction; promotion of tumor inflammation; abnormal cell energy metabolism; genomic instability and mutation, etc., it has created huge obstacles for the treatment of the disease. Therefore, it is difficult for a single treatment method to exert therapeutic benefits. For the treatment of tumors, a combination of multiple methods is often used, such as surgical resection, radiotherapy and chemotherapy. Among them, due to the rapid progression of cancer, the best time for surgical treatment and radiotherapy is often missed at the time of diagnosis, and chemotherapy drugs are needed to prolong the survival of patients. Therefore, some anti-tumor compounds with excellent efficacy are urgently needed in the clinic. At present, most clinical anti-tumor drugs partially or completely exert their anti-tumor effects through apoptosis, such as platinum compounds, paclitaxel, irritron, gemcitabine, temozolomide, pemetrexed, imatinib, etc. In long-term clinical use, these drugs will induce apoptosis resistance in cancer cells, making it difficult to kill tumor cells and bring good therapeutic benefits to patients. In response to this problem, developing new drugs that induce non-apoptotic cell death is one of the strategies to kill tumor cells and overcome apoptosis resistance. Among various forms of non-apoptotic cell death, ferroptosis mediated by lipid peroxidation discovered by Dixon in 2012 is a good anti-tumor strategy.

[0003] Ferroptosis is mainly regulated by iron ions, lipid peroxidation and thiol reduction systems. Under the action of divalent iron or esteroxygenase, it catalyzes unsaturated fatty acids highly expressed on the cell membrane to cause lipid peroxidation, thereby inducing cell death. Under normal circumstances, GPX4, the core enzyme that regulates the antioxidant system (glutathione system), inhibits the above pathways through a feedback mechanism, and GPX4 disorder can also induce ferroptosis. Currently available ferroptosis inducers such as Erastin and soraferib work mainly by regulating the thiol reduction system to inhibit lipid peroxide reduction. Drugs that regulate iron ion metabolism are relatively rare. In the early studies of our research group, we mainly used MOF-Fe nanoformulations to deliver Fe 2+To induce ferroptosis, it was found that MOF-Fe can effectively deliver iron ions into the tumor and kill some tumor cells, but the intracellular Fe 2+ The increase will also increase the cell's protective mechanism, causing the upregulation of FTH1, which will overload the Fe 2+ Therefore, in order to release Fe from the protein, induce iron overload, and further kill tumor cells, ferritin needs to be degraded. However, due to the particularity of ferritin structure, there are currently no targeted ferritin inhibitors.

[0004] The protein degradation targeting chimeras (PROTACs) in chemical biology are a class of bifunctional small molecule compounds based on the ubiquitin-proteasome system that chemically induces the polyubiquitination and degradation of target proteins. The structure contains two ligands: one end is a ligand that can recruit the protein degradation system (such as E3 ubiquitin ligase), and the other end is a ligand that binds to the target protein in the cell. The two ligands are connected by a linker. After PROTACs enter the cell, the ligands at both ends specifically bind to the corresponding protein, bringing the target protein and the E3 ubiquitin ligase in the cell closer to form a "target protein PROTAC-E3" ternary complex, in which the E3 ubiquitin ligase can mediate the ubiquitination of the target protein by the ubiquitin-binding enzyme E2. After the ternary complex dissociates, the dissociated PROTACs can bind to the protein again, and the target protein "tagged" by ubiquitin is recognized and degraded by the proteasome, thereby selectively reducing the level of the target protein in the cell.

[0005] Ferritin is a widely-existing iron storage protein, which consists of 24 subunits in a highly symmetrical manner and a hollow protein shell with a diameter of about 8nm. The protein shell surrounds an iron core composed of iron and phosphate molecules, with an outer diameter of 12-13nm and a molecular weight of 500kDa. Ferritin from different sources varies greatly in primary structure, making the design of specific inhibitors more difficult. Therefore, the use of chemical biology PROTACs to design synthetic ferritin has good application prospects.

[0006] The iron storage protein ferritin contains fatty acid binding sites, which regulate the absorption and release of iron and can therefore serve as a binding ligand for ferritin. In the ferroptosis metabolic pathway, monounsaturated fatty acids often inhibit the occurrence of ferroptosis, while polyunsaturated fatty acids promote ferroptosis. The use of polyunsaturated fatty acids to synthesize a series of ferritin degraders may have better therapeutic effects.

[0007] The molecular weight of PROTACs is generally between 600 and 1300, which is a relatively large molecular weight among small molecules. In addition, because the molecular design does not conform to the "five principles of drug-likeness", the membrane permeability and bioavailability of the compound are poor, and the drug performance is poor. Therefore, in order to further improve the in vivo bioavailability and drug performance of the drug, it is necessary to further improve it through a certain drug dosage form design. MOF-Fe@PROTAC@PEI has good solubility, high in vivo bioavailability, and can also deliver iron ions to the interior of the cell, exerting a synergistic sensitization effect with ferritin PROTAC.

[0008] Therefore, developing highly efficient and targeted ferritin degradation drugs through PROTAC drug development technology using simple chemical means will have broader application prospects and market value. Summary of the invention:

[0009] The purpose of the present invention is to provide a ferroptosis-inducing nano dosage form targeting ferritin and a preparation method and application thereof, so as to solve the deficiencies of the prior art.

[0010] The present invention is implemented by the following technical scheme: On the one hand, the present invention provides a compound of general formula I:

[0011]

[0012] in, represents the ligand of E3 ubiquitin ligase;

[0013] The -L- represents a linking group, which may be unsubstituted or optionally contain one or more heteroatoms. 1-50 The heteroatom may be selected from O, S, and N.

[0014] Said Represents various saturated or unsaturated long alkyl chains, which are formed by the reaction of saturated or unsaturated fatty acids and their acyl halides, anhydride derivatives and amino groups. The above saturated or unsaturated fatty acids can be selected from palmitic acid, oleic acid, linoleic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid, etc.

[0015] According to an embodiment of the present invention, the It can be selected from conventional E3 ubiquitin ligase ligands (those skilled in the art of pharmacy can understand that the ligand is connected to -L- at any suitable site). Examples of the ligand structure are as follows:

[0016] CRBN

[0017]

[0018] VHL

[0019]

[0020] DCAF

[0021]

[0022] According to a preferred embodiment of the present invention, You can choose the following structure:

[0023]

[0024] According to an embodiment of the present invention, the general formula I is further selected from the following formula II, formula III, and formula IV structures:

[0025]

[0026] In the general formula II, -L-, As defined above;

[0027]

[0028] In the general formula III, As defined above, n is selected from 1-100;

[0029]

[0030] In the general formula IV, As defined above, n is selected from 1-100;

[0031] The present invention provides a method for preparing a compound of general formula I, comprising the following steps:

[0032] 1) VHL-Ligand

[0033]

[0034] 2) Ferrtin PROTAC

[0035]

[0036] According to an embodiment of the present invention, the preparation method of the general formula I may further include one or more of the following steps:

[0037] Step 1: Synthesis of c, d molecules:

[0038] Compound a was dissolved in organic reagent A, Boc-protected amino acid molecules (1.2 eq) of different lengths were selected, condensation reagent A was added, nitrogen was protected, and the reaction was carried out at room temperature for 2-4 hours, and the crude product was extracted with 5% sodium carbonate solution and organic reagent B, and the target product c was purified by silica gel column. The synthesis of molecule d was the same as molecule c.

[0039] Step 2: Synthesis of e and f molecules:

[0040] Molecule c was dissolved in dichloromethane, and hydrochloric acid (4M)-1,4-dioxane (3 eq) was added, and the mixture was reacted at room temperature for 30 minutes. The crude product e was obtained after rotary evaporation. The synthesis of molecule e was similar to that of molecule f.

[0041] Step 3, synthesis of OALnV, OALnOV molecules:

[0042] Dissolve compound e in organic reagent A, select different fatty acids or their anhydrides, acyl halide derivatives (1eq), add condensation reagent C (2eq) and the alkali solution used in combination, protect with nitrogen, react at room temperature overnight, extract with 5% sodium carbonate solution and organic reagent B to obtain the crude product, and purify with silica gel column to obtain the target product OALnV. The synthesis of molecule OALnV is as molecule OALnOV.

[0043] According to an embodiment of the present invention, in the preparation method of the compound of general formula I, the organic reagent A is selected from dimethyl sulfoxide, N,N-dimethylformamide, acetonitrile, and dichloromethane; the organic reagent B is selected from ethyl acetate and dichloromethane; the condensation reagent C is selected from O-(7-azabenzotriazole-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HATU), N,N'-carbonyldiimidazole (CDI), and N,N,N',N'-tetramethylchloroformamidine hexafluorophosphate (TCFH).

[0044] According to the embodiments of the present invention, those skilled in the art of pharmacy can understand that in the above preparation method, any intermediate can be selected to synthesize the final product.

[0045] On the other hand, the present invention provides a cationic polyimine-wrapped MOF-Fe nanoparticle, which is loaded with the compound of general formula I according to claim 1.

[0046] According to an embodiment of the present invention, the MOF-Fe nanoparticles, the MOF-Fe is loaded with the compound of general formula I through the internal pores, and the surface of MOF-Fe@PROTAC is wrapped by cationic polyimine to prepare a MOF-Fe@PROTAC@PEI complex.

[0047] According to an embodiment of the present invention, the nanoparticles and the cationic polyimine include one or more of polyetherimide (PEI) and polyoxyamine (ODA).

[0048] According to the above-mentioned method for preparing MOF-Fe nanoparticles, the following steps are included:

[0049] (1) Add 2-aminoterephthalic acid (NH2-BDC) and iron (III) chloride hexahydrate (FeCl3.6H2O) into a reactor at 110°C for 48 hours.

[0050] (2) After drying in an oven at 100°C, PROTAC was added, ultrasonically dispersed, and incubated at room temperature for 24 h.

[0051] (3) The nanoparticles were washed by centrifugation, incubated with cationic polyimine for 24 h, and the precipitate was collected by centrifugation and resuspended.

[0052] In another aspect, the present invention provides the use of the compound of formula I or its nano drug MOF-Fe@PROTAC@PEI in the preparation of anti-tumor drugs. According to some preferred embodiments of the present invention, the tumors include: human pancreatic ductal carcinoma (PANC-1, MIAPACA2) and mouse cell line KPC-A719 pancreatic cancer cells (LSL-Kras G12D / + ;LSL-Trp53 R172H / + ; Pdx-1-Cre).

[0053] In another aspect, the present invention provides the use of the compound of formula I or its nano drug MOF-Fe@PROTAC@PEI in the preparation of an ferroptosis inducer. According to an embodiment of the present invention, the ferroptosis inducer can prevent and / or treat conditions including neurodegenerative diseases, traumatic and hemorrhagic brain injury, ischemic injury (liver, kidney and heart ischemic injury)

[0054] In some embodiments, the disorder includes Parkinson's disease (PD), Huntington's disease (HD), and Alzheimer's disease (AD).

[0055] Advantages of the present invention:

[0056] 1. The present invention uses polyunsaturated fatty acids and (2S,4R)-1-((S)-2-amino-3,3-dimethylbutyryl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride that recruits E3 ubiquitin ligase, and matches the optimized linker to form the Ferritin-PROTAC series structure shown in the general formula II, III, and IV. Studies have found that the PROTAC can indeed cause ferritin to degrade in different cell lines, as well as in cells with high and overexpressed ferritin, and further induce ferroptosis. Studies have shown that the combination of Ferritin-PROTAC and MOF-Fe can play a strong synergistic role and further enhance the tumor killing effect of Ferritin-PROTAC.

[0057] 2. The inventor team found through experimental research that the compound series of general formula II, III, and IV have a high efficiency in killing pancreatic cancer cells, especially C20U4LV with arachidonic acid as the ferritin ligand has the highest degradation efficiency and a high tumor killing effect. The ROS content on the membrane measured by BODIPY "581 / 591C11 increased with the concentration, further confirming the occurrence of ferroptosis. MTT cytotoxicity experiments were performed to compare different pancreatic cancer cell lines, confirming that C20U4LV can work on different cell lines, and the effect is better in the ferritin-overexpressing cell MIAPACA2, and it also has a good protein degradation effect on the simulated drug-resistant cell line PANC-1 cells with overexpression of ferritin.

[0058] 3. The present invention team further discovered that the combination of MOF-Fe and Ferritin-PROTAC has a strong tumor killing effect and enhances the efficacy of ferroptosis. Therefore, a MOF-Fe@PROTAC@PEI drug delivery strategy was designed, which uses cationic PEI to improve the efficiency of PROTAC small molecule delivery, increase the stability of nanomedicines, and increase the water solubility of drugs, thereby further improving the targeting of such drugs and reducing toxic effects on normal cells. Description of the drawings:

[0059] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0060] Figure 1 Schematic diagram of the structure and action mechanism of the optimal ferritin PROTAC degrader C18U2L3V.

[0061] Figure 2 Schematic diagram of IC values ​​of different compounds 50 (cell viability) and AUC area (drug sensitivity).

[0062] Figure 3 Schematic diagram of the effect of the combined use of iron-based metal organic framework (MOF-Fe) and ferritin PROTAC degrader C20U4LV on the proliferation of PANC-1 cells.

[0063] Figure 4 Illustration of the ferritin degradation activity and statistical results of C20U4LV, C20U4L4V, C20U2L3V, and C20U3L4OV combined with MOF-Fe.

[0064] Figure 5Schematic diagram of the degradation activity of C20U4LV combined with MOF-Fe on ferritin of the human pancreatic cancer cell line PANC-1 under the action of ubiquitin ligase ligand (2S,4R)-1-((S)-2-amino-3,3-dimethylbutyryl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride (VHL-ligand).

[0065] Figure 6 Schematic scanning electron microscope (SEM) image of MOF-Fe@C20U4LV@PEI.

[0066] Figure 7 1H-NMR result of C18U2L3V.

[0067] Figure 8 This is the 13C-NMR result of C18U2L3V.

[0068] Fig. 9 This is the ESI mass spectrum of C18U2L3V.

[0069] Fig.10 1H-NMR result of C18U2L4OV.

[0070] Fig.11 13C-NMR results of C18U2L4OV.

[0071] Fig.12 This is the ESI mass spectrum of C18U2L4OV.

[0072] Fig.13 1H-NMR result of C20U4LV.

[0073] Fig.14 13C-NMR results of C20U4LV.

[0074] Fig.15 This is the ESI mass spectrum of C20U4LV.

[0075] Fig.16 1H-NMR result of C20U4L4V.

[0076] Fig.17 This is the 13C-NMR result of C20U4L4V.

[0077] Fig.18 This is the ESI mass spectrum of C20U4L4V.

[0078] Fig.19 1H-NMR result of C18U1L3V.

[0079] Fig. 2013C-NMR results of C18U1L3V.

[0080] Fig.21 This is the ESI mass spectrum of C18U1L3V. Specific implementation method:

[0081] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0082] Unless otherwise specified, the raw materials and reagents used in the following examples are commercially available or can be prepared by known mature methods.

[0083] Example 1 Synthesis of C20U4LV: (when n=0)

[0084] C20U4LV

[0085]

[0086] Step 1: Synthesis of C20U4LV: (2S,4R)-1-((S)-2-amino-3,3-dimethylbutyryl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride (1eq, 100mg) and arachidonic acid (1.5eq, 97mg) that recruit E3 ubiquitin ligase were dissolved in the organic reagent DMF, and condensation reagents HATU (2eq, 155mg) and DIPEA (6eq, 120mg) were added. The reaction was carried out at room temperature overnight under nitrogen protection, and the crude product was extracted with 5% sodium carbonate solution and DCM, and purified with a silica gel column to obtain a light yellow solid. 1 H NMR(600MHz, CDCl3)δ8.69(s,1H),7.38–7.31(m,4H),6.33(d,J=9.0Hz,1H),5.41–5.32(m,8H),4.69(t,J=7.9Hz,1H),4.59–4.51 (m,3H),4.33(dd,J=15.0,5.3Hz,1H),4.06(d,J=11.4Hz,1H),3.64(dd,J=11.2,3.8Hz,1H),2.88–2.76(m,7H),2.51(s,3H),2.49–

[0087] 2.45(m,1H),2.33(t,1H),2.20(t,J=7.4Hz,2H),2.16–2.01(m,5H),1.74–1.61 (m,3H),1.36(q,J=7.5Hz,2H),1.26(s,1H),0.94(s,9H),0.88(t,J=7.0Hz,3H). 13 C NMR (151MHz, CDCl3) δ176.65,173.63,171.87,170.83,150.44,148.39,138.10,131.63,130.91,130.52,130 .50,129.51,128.95,128.91,128.86,128.63,128.59,128.29,128.23,128.15,128.11,128.07,127.86,127. 83,127.54,127.51,70.00,58.70,57.45,56.77,43.22,36.01,35.84,35.10,33.44,31.51,29.69,29.31,27 .22,26.62,26.58,26.41,25.64,25.62,25.47,24.77,22.57,16.00,14.09.ESI-MS(m / z):[M+Na]calculated forC 42 H 60 N4O4S:739.4233;

[0088] found 739.420.

[0089] Example 2

[0090] Referring to the synthesis of Example 1, oleic acid was used as the raw material for substitution to synthesize the C18U1LV molecule (the structure is shown below).

[0091]

[0092] 1H NMR (600MHz, CDCl3) δ8.66 (s, 1H), 7.33 (q, J = 8.1Hz, 5H), 6.17 (t, J = 9.2Hz, 1H),5.35–5.28(m,2H),4.69–4.65(m,1H),4.55–4.48(m,3H),4.33(dd,J=15 .0,5.4Hz,1H),4.03(d,J=9.1Hz,1H),3.73–3.65(m,2H),3.62(dd,J=11.2, 3.8Hz,1H),3.17(q,J=7.7Hz,2H),2.49(s,3H),2.15(t,J=7.7Hz,2H),2.12–

[0093] 2.07(m,1H),1.98(q,J=7.2Hz,4H),1.32–1.22(m,20H),0.92(s,9H),0.86(t,J=6.9Hz,3H).

[0094] 13 C NMR (151MHz, CDCl3) δ173.79,171.79,170.88,150.35,148.44,138.11,131.60,130.9 3,130.03,129.70,129.50,128.07,70.02,58.70,57.45,56.69,55.81,55.73,43.64, 43.20,36.55,31.90,29.76,29.70,29.52,29.32,29.23,29.20,29.14,27.22,27.17, 26.42,25.67,22.68,18.53,18.19,17.10,16.67,16.05,14.13,12.62.ESI-MS(m / z):

[0095] [M+Na]calculated for C 40 H 62 N4O4S:717.4384; found 717.437

[0096] Example 3

[0097] Referring to the synthesis of Example 1, oleic acid was used as the raw material for substitution to synthesize the C18U3LV molecule (the structure is shown below).

[0098]

[0099] 1H NMR (600MHz, CDCl3) δ8.66 (s, 1H), 7.33 (p, J=

[0100] 8.6Hz,5H),6.15(d,J=8.7Hz,1H),5.41–5.25(m,6H),4.69(t,J=7.9Hz,1H),4.58–4.47(m,3H),4.32(dd,J=15.0,5.3Hz,1H),4.0 6(d,J=11.4Hz,1H),3.71–3.67(m,4H),3.60(dd,J=11.3,3.7Hz,1H),2.50(s,3H),2.17(t,J=7.6Hz,2H),2.08–2.00(m,5H),1.60

[0101] –1.55(m,2H),1.28–1.24(m,7H),0.95(t,J=7.5Hz,3H),0.91(s,9H). 13 C NMR (151MHz, CDCl3) δ173.79,171.95,170.74,162.70,150.34,148.44,138.10,131.97,131.62 ,130.95,130.25,129.53,128.30,128.24,128.13,127.74,127.11,70.04,58.52,57.45,56.63 ,55.45,43.45,43.25,36.58,36.52,35.85,34.92,31.48,29.58,29.22,29.19,29.13,27.20,2 6.42,25.62,25.53,20.55,18.55,17.10,16.05,14.29,12.67.ESI-MS(m / z):[M+Na]calculated for C 40 H 58 N4O4S:713.4071; found 713.402

[0102] Example 4

[0103] Referring to the synthesis of Example 1, cis-5,8,11,14,17-eicosapentaenoic acid was used as the raw material for substitution to synthesize the C20U5LV molecule (the structure is shown below).

[0104]

[0105] 1H NMR (600MHz, CDCl3) δ8.67(s,1H),8.00(s,1H),7.37–7.32(m,4H),7.29(t,J=6.0Hz,1H),6.15(d,J=8.7Hz,1H ),5.42–5.26(m,10H),4.70(t,J=7.9Hz,1H),4.59–4.48(m,3H),4.32(dd,J=14.9,5.2Hz,1H),4.08(d,J=11.5 Hz,1H),3.75–3.67(m,2H),3.60(dd,J=11.3,3.7Hz,1H),3.21–3.14(m,2H),2.50(s,3H),2.19(t,J=7.7Hz,2H ),2.11–2.02(m,4H),1.66(dd,J=13.6,7.5Hz,2H),1.41(d,J=6.6Hz,6H),0.96(t,J=7.5Hz,3H),0.92(s,8H). 13 C NMR (151MHz,CDCl3)δ

[0106] 173.61,171.93,170.68,162.68,150.35,148.45,138.06,132.06,131.61,130.98,129.54,128.89,128.60,128.31,128.20,128.13,128.07,127.85,127.00,70.06,58.49,

[0107] 57.50,56.66,55.63,43.59,43.27,36.56,35.84,35.79,34.87,31.48,26.62,26.41,25.63 ,25.55,25.43,20.56,18.58,17.16,16.04,14.28,12.59.ESI-MS(m / z):[M+Na]calculated for C 42 H 58 N4O4S:737.4071; found 737.404.

[0108] Example 5 Synthesis of C20U4L1V: (when n=1)

[0109]

[0110] Step 1. Synthesis of compound 1: (2S,4R)-1-((S)-2-amino-3,3-dimethylbutyryl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride (1eq, 100mg) and arachidonic acid (1.5eq, 97mg) that recruit E3 ubiquitin ligase were dissolved in the organic reagent DMF, and condensation reagents HATU (2eq, 155mg) and DIPEA (6eq, 120mg) were added. The reaction was carried out at room temperature overnight under nitrogen protection, and the crude product was extracted with 5% sodium carbonate solution and DCM, and purified by silica gel column to obtain a light yellow solid.

[0111] Step 2, synthesis of compound 2:

[0112] The molecule 1 was dissolved in dichloromethane, and hydrochloric acid (4M)-1,4-dioxane (3eq) was added, and the mixture was reacted at room temperature for 30 minutes. The crude product 2 was obtained after rotary evaporation.

[0113] Step 3, synthesis of compound C20U4L1V:

[0114] Compound 2 and arachidonic acid (1.5 eq, 74.3 mg) were dissolved in the organic reagent acetonitrile, and condensation reagents HATU (2 eq, 155 mg) and DIPEA (6 eq, 150 mg) were added. The mixture was protected by nitrogen and reacted at room temperature overnight. The crude product was extracted with 5% sodium carbonate solution and DCM, and purified by silica gel column to obtain a white solid.

[0115] 1 H NMR (600MHz, CDCl3) δ8.68 (s, 1H), 8.01 (t, J=

[0116] 6.0Hz,1H),7.54(d,J=9.3Hz,1H),7.34(q,4H),6.71(t,J=4.7Hz,1H),5.42–5.30(m,8H),4.77(t,J=8.2Hz, 1H),4.71(d,J=9.4Hz,1H),4.57(dd,J=15.1,6.5Hz,1H),4.51(s,1H),4.30(dd,J=15.1,5.3Hz,1H),4.01–3 .88(m,3H),3.73(dd,J=11.1,3.6Hz,1H),2.82–2.79(m,4H),2.50(s,3H),2.36–2.22(m,3H),2.22–2.18(m, 2H),2.06(dq,J=14.5,7.3Hz,4H),1.74–1.61(m,3H),1.38–1.24(m,7H),0.98(s,9H),0.88(t,J=7.0Hz,3H).13 C NMR (151MHz, CDCl3) δ174.02,171.38,171.07,169.02,150.38,148.41,138.30,131.57, 130.83,130.55,129.44,128.95,128.82,128.67,128.36,128.05,127.86,127.79,127.5 0,70.18,58.75,57.52,57.50,43.07,43.02,37.49,35.91,35.68,31.51,29.31,27.22,2 6.69,26.52,25.64,25.62,25.52,22.57,16.06,14.09.ESI-MS(m / z):[M+Na]calculated for C 44 H 62 N4O5S:796.4078; found796.450.

[0118] Example 6

[0119] Referring to the synthesis of Example 5, linoleic acid was used as the raw material in step 3 to synthesize the C18U2L1V molecule (the structure is shown below).

[0120]

[0121] 1 H NMR (600MHz, CDCl3) δ8.69(s,1H),7.81(s,1H),7.33(q,J=8.2Hz,4H),6.65(s,1H),6.36(s,1H),5.41–

[0122] 5.27(m,4H),4.75(t,J=8.3Hz,1H),4.62(d,J=9.0Hz,1H),4.55–4.49(m,2H),4.31(dd ,J=15.1,5.4Hz,1H),3.96(t,J=14.6Hz,2H),3.91–3.85(m,1H),3.75–3.67(m,3H),3.2 1–3.14(m,3H),2.75(t,J=6.8Hz,2H),2.50(s,3H),2.27–2.22(m,1H),2.21–2.14(m,2H ),2.03(p,J=7.1Hz,4H),1.38–1.22(m,12H),1.04–0.91(m,9H),0.88(t,J=6.8Hz,3H). 13C NMR (150MHz, CDCl3) δ174.50,171.43,171.30,169.46,150.57,148.30,138.48,131.86,1 30.82,130.39,130.11,129.56,128.22,128.05,128.00,70.39,58.87,57.81,57.42,55.7 9,43.73,43.23,43.20,37.36,36.45,35.79,35.77,31.64,29.76,29.46,29.42,29.28,27 .33,26.61,25.81,25.76,22.70,18.69,17.29,17.27,16.09,14.21,12.68.ESI-MS(m / z):

[0123] [M+Na]calculated for C 42 H 63 N4O5S:772.455; found:772.440.

[0124] Example 7

[0125] Referring to the synthesis of Example 5, linolenic acid was used as the raw material in step 3 to synthesize the C18U3L1V molecule (the structure is shown below).

[0126]

[0127] 1 H NMR (600MHz, CDCl3) δ8.65(s,1H),8.01(t,J=6.0Hz,1H),7.49(d,J=9.2Hz,1H),7.31(q,J=8.2Hz,4H),6.78(t,J= 4.8Hz,1H),5.41–5.25(m,6H),4.74(t,J=8.2Hz,1H),4.67(d,J=9.3Hz,1H),4.54–4.47(m,2H),4.29(dd,J=15.2, 5.4Hz,1H),3.96–3.89(m,3H),3.75–3.67(m,2H),3.19–3.13(m,1H),2.78(q,J=5.6Hz,3H),2.48(s,3H),2.25(d, J=5.4Hz,2H),2.20–2.12(m,2H),2.09–1.98(m,4H),1.54(q,J=7.4Hz,2H),1.44–1.37(m,6H),1.00–0.92(m,12H). 13C NMR (151MHz, CDCl3) δ174.36,171.47,171.01,169.12,150.32,148.41,138.34,131.97, 131.56,130.80,130.17,129.41,128.33,128.20,127.84,127.79,127.09,70.17,58.80,

[0128] 57.48,55.59,43.53,43.03,37.59,36.31,35.91,31.51,29.61,29.33,29.31,29.17,27.21,26.52 ,25.70,25.62,25.53,20.55,18.56,17.15,16.09,14.29,12.56.ESI-MS(m / z):[M+Na]calculated for C 42 H 60 N4O5S:771.3921; found:771.424.

[0129] Example 8

[0130] Referring to the synthesis of Example 5, step three uses cis-5,8,11,14,17-eicosapentaenoic acid as the raw material for substitution to synthesize the molecule C20U5L1V (structure shown below).

[0131]

[0132] 1 H NMR (600MHz, CDCl3) δ8.67(s,1H),7.96(t,J=6.0Hz,1H),7.46(d,J=9.2Hz,1 H),7.33(q,J=8.3Hz,4H),6.72(t,J=4.8Hz,1H),5.43–5.27(m,10H),4.76(t ,J=8.2Hz,1H),4.68(d,J=9.2Hz,1H),4.55(dd,J=15.1,6.4Hz,1H),4.51(s, 1H),4.31(dd,J=15.1,5.4Hz,1H),3.99–3.88(m,3H),3.74–3.69(m,2H),3.21

[0133] –3.16(m,3H),2.83(d,J=6.1Hz,2H),2.50(s,3H),2.31–2.25(m,2H),2.23–2.18(m,2H),2.07(p,J=

[0134] 7.4Hz, 4H), 1.65 (p, J = 7.6Hz, 2H), 1.42 (d, J = 6.6Hz, 4H), 1.01–0.94 (m, 12H). 13 CNMR (151MHz,CDCl3)δ

[0135] 174.05,171.40,171.08,169.08,150.32,148.43,138.30,132.06,131.57,130.82,129.43,128.90,128.86,128.61,128.33,128.27,128.12,128.03,128.03,127.86, 127.84,127.00,70.21,58.76,57.56,57.41,55.67,43.60,43.06,37.46,35.83,35.68,26.69,26.51,25.62,25.54,25.53,20.56,18.55,17.14,16.09,14.29,12.58.

[0136] ESI-MS(m / z):[M+K]calculated for C 44 H 60 N4O5S:794.4182; found:794.425.

[0137] Example 9

[0138] Referring to the synthesis of Example 5, step 3 was replaced by using 13-docosaenoic acid as the raw material to synthesize the C22U1L1V molecule (the structure is shown below).

[0139]

[0140] 1H NMR(600MHz, CDCl3)δ8.66(s,1H),7.85(s,1H),7.37–7.28(m,4H),6.63(s,1H),5.36–5.30(t,2H),4.76(t, J=8.2Hz,1H),4.64(d,J=9.1Hz,1H),4.57–4.49(m,2H),4.31(dd,J=15.1,5.4Hz,1H),4.00–3.92(m,2H),3.8 8(dd,J=17.0,5.0Hz,1H),3.75–3.67(m,2H),3.21–3.14(m,1H),2.50(s,3H),2.37–2.29(m,1H),2.28–2.21( m,1H),2.18(t,J=7.8Hz,2H),2.00(q,J=6.6Hz,4H),1.36–1.21(m,28H),0.97(s,9H),0.87(t,J=7.0Hz,3H). 13 C NMR (151MHz, CDCl3) δ174.50,171.37,171.30,169.38,150.42,148.60,138.38,131.68,13 1.02,130.07,129.99,129.58,128.04,70.39,58.82,57.78,57.48,55.84,43.79,43.23,3 7.38,36.50,35.81,32.04,29.94,29.91,29.79,29.74,29.66,29.52,29.49,29.46,27.36 ,26.63,25.83,22.82,18.74,17.37,16.23,14.26,12.63.ESI-MS(m / z): [M+Na]calculated for C 46 H 73 N5O5S(M+Na):830.533,found:830.521.

[0141] Example 10

[0142] Referring to the synthesis of Example 5, step 2 was replaced by using N-Boc-γ-aminobutyric acid as the raw material to synthesize the C20U4L3V molecule (the structure is shown below).

[0143]

[0144] 1H NMR (600MHz, CDCl3) δ8.68(s,1H),7.44(t,J=6.0Hz,1H),7.35(q,4H),7.00(d,J=8.3Hz,1H),6.01(t,J=5.9Hz, 1H),5.46–5.28(m,8H),4.74(t,J=8.1Hz,1H),4.57–4.48(m,3H),4.33(dd,J=15.0,5.4Hz,1H),4.09(d,J=11.3H z,1H),3.61(dd,J=11.3,3.6Hz,1H),3.33–3.17(m,2H),2.83–2.78(m,4H),2.51(s,3H),2.27–2.11(m,7H),2.1 2–2.02(m,4H),1.79–1.72(m,2H),1.68(p,J=7.5Hz,2H),1.39–1.24(m,7H),0.96(s,9H),0.88(t,J=6.9Hz,3H). 13 C NMR (151MHz, CDCl3) δ173.71,173.29,172.00,170.90,150.32,148.47,138.16,131.59,130 .95,130.55,129.51,129.06,128.81,128.65,128.31,128.11,128.08,127.82,127.50,70.1 3,58.44,58.12,56.85,43.19,38.46,36.19,36.07,34.95,33.18,31.51,29.32,27.23,26. 70,26.48,26.03,25.65,25.63,25.58,22.57,16.06,14.09.ESI-MS(m / z):[M+K]calculated for C 46 H 66 N4O5S(M+K):824.4652,found:824.483.

[0145] Embodiment 11

[0146] Referring to the synthesis of Example 5, step 2 was replaced by N-Boc-γ-aminobutyric acid as the raw material, and step 3 was replaced by oleic acid as the raw material to synthesize the C18U1L3V molecule (the structure is shown below).

[0147]

[0148] 1H NMR(600MHz, DMSO-d6)δ8.98(s,1H),8.56(t,J=6.1Hz,1H),7.90(d,J=9.3Hz,1H),7.73(t,J=5.6Hz,1H),7.45–7.36(m,4H),5.31(t,J=4.9H z,2H),5.13(d,J=3.6Hz,1H),4.53(d,J=9.3Hz,1H),4.46–4.40(m,2H),4.35(s,1H),4.21(dd,J=15.8,5.5Hz,1H),3.67(dd,J=10.5,4.1Hz, 1H),3.63(d,J=10.8Hz,1H),3.16–3.12(m,1H),3.05–2.95(m,2H),2.44(s,3H),2.28–2.20(m,1H),2.16–2.08(m,1H),2.02(t,J=7.4Hz,2H) ,1.97(q,J=6.5Hz,4H),1.93–1.87(m,1H),1.64–1.53(m,2H),1.46(p,J=7.4Hz,2H),1.31–1.18(m,20H),0.93(s,3H),0.84(t,J=6.9Hz,3H). 13 C NMR(150MHz,DMSO-d6)δ172.46,172.42,172.23,170.13,139.97,131.63,130.10,129.1 1,127.89,69.35,59.17,56.84,56.83,54.07,42.32,42.12,38.57,38.41,35.91,35.72 ,33.01,31.74,29.59,29.55,29.28,29.16,29.14,29.04,29.01,27.06,27.03,26.85,2 6.26,25.76,22.55,18.56,17.20,16.41,14.42,12.96.ESI-MS(m / z):[M+Na]calculated for C 44 H 69 N5O5S(M+K):802.4917,found:802.490.

[0149] Example 12

[0150] Referring to the synthesis of Example 5, step 2 was replaced by N-Boc-γ-aminobutyric acid as the raw material, and step 3 was replaced by linoleic acid as the raw material to synthesize the C18U2L3V molecule (the structure is shown below).

[0151]

[0152] 1 H NMR (600MHz, DMSO) δ8.98(s,1H),8.56(t,J=6.1Hz,1H),7.89(d,J=9.3Hz,1H),7.73(t,J=5.6Hz,1H),7.46–7.37(m,4H ),5.38–5.25(m,4H),5.13(d,J=3.6Hz,1H),4.53(d,J=9.4Hz,2H),4.46–4.40(m,2H),4.35(s,1H),4.21(dd,J=15.8,5. 6Hz,1H),3.70–3.60(m,2H),3.05–2.94(m,2H),2.73(t,J=6.8Hz,2H),2.44(s,3H),2.28–2.20(m,1H),2.16–2.07(m,1H ),2.01(p,J=7.3Hz,6H),1.94–1.86(m,1H),1.66–1.52(m,1H),1.33–1.18(m,16H),0.93(s,9H),0.85(t,J=6.9Hz,3H). 13 C NMR (150MHz, DMSO) δ172.47,172.42,172.24,170.13,151.92,148.18,139.97,131.64,1 30.21,130.19,130.10,129.11,128.22,127.89,70.25,69.34,59.17,56.84,42.12,40.5 1,38.58,38.41,35.91,35.72,33.01,31.36,29.50,29.18,29.14,29.14,29.04,27.10,2 7.07,26.85,26.27,25.77,25.69,22.44,16.41,14.40.ESI-MS(m / z):[M+Na]calculated for C 44 H 67 N5O5S(M+Na):800.486,found:800.474.

[0153] Embodiment 13

[0154] Referring to the synthesis of Example 5, step 2 was replaced by N-Boc-γ-aminobutyric acid as the raw material, and step 3 was replaced by linolenic acid as the raw material to synthesize the C18U3L3V molecule (the structure is shown below).

[0155]

[0156] 1 H NMR (600MHz, CDCl3) δ8.66(s,1H),7.47(t,J=6.0Hz,1H),7.32(q,J=8.3Hz,4H),7.06(d,J=8.4Hz,1H),6.16(t, J=6.0Hz,1H),5.42–5.25(m,6H),4.71(t,J=8.1Hz,1H),4.56–4.45(m,3H),4.32(dd,J=15.1,5.5Hz,1H),3.61( dd,J=11.3,3.6Hz,1H),3.29–3.12(m,2H),2.81–2.75(m,3H),2.49(s,3H),2.44–2.37(m,1H),2.25–2.10(m,5H ),2.10–1.99(m,4H),1.72(p,J=7.0Hz,2H),1.56(p,J=8.6Hz,2H),1.34–1.22(m,10H),0.95(d,J=3.6Hz,12H). 13 C NMR (151MHz, CDCl3) δ174.05,173.35,171.87,171.06,150.34,148.42,138.20,131.97,1 31.60,130.88,130.21,129.47,128.31,128.21,128.01,127.76,127.09,70.11,58.62,58 .09,56.89,43.14,38.52,36.71,36.45,35.08,33.17,29.61,29.32,29.30,29.17,27.20, 26.48,25.93,25.80,25.61,25.52,20.55,16.05,14.29.ESI-MS(m / z):[M+Na]calculated for C 44 H 64 N5O4S 760.4597,found:798.4234.

[0157] Embodiment 14

[0158] Referring to the synthesis of Example 5, step 2 was replaced by N-Boc-γ-aminobutyric acid as the raw material, and step 3 was replaced by cis-5,8,11,14,17-eicosapentaenoic acid as the raw material to synthesize the C20U5L3V molecule (structure shown below).

[0159]

[0160] 1 1H NMR (600 MHz, CDCl3) δ 8.68 (s, 1H), 7.46 (t, J = 6.1 Hz, 1H), 7.34 (q, J = 8.4 Hz, 4H), 7.08 (d, J = 8.4 Hz, 1H), 6.16 (t, J = 5.9 Hz, 1H), 5.42–5.31 (m, 10H), 4.73 (t, J = 8.1 Hz, 1H), 4.57–4.47 (m, 3H), 4.34 (dd, J = 15.1, 5.5 Hz, 1H), 4.07 (d, J = 11.5 Hz, 1H), 3.71 (p, J = 6.7 Hz, 1H), 3.63 (dd, J = 11.3, 3.6 Hz, 1H), 3.30–3.15 (m, 3H), 2.51 (s, 3H), 2.47–2.42 (m, 1H), 2.36–2.30 (m, 1H), 2.26–2.19 (m, 2H), 2.19–2.14 (m, 4H), 2.07 (pt, J = 7.6, 3.1 Hz, 4H), 1.78–1.71 (m, 2H), 1.71–1.64 (m, 2H), 1.47–1.41 (m, 4H), 0.99–0.94 (m, 12H). 13 13C NMR (151 MHz, CDCl3) δ 173.78, 173.37, 171.91, 171.05, 150.37, 148.40, 138.20, 132.07, 131.63, 130.87, 129.48, 129.08, 128.75, 128.61, 128.31, 128.22, 128.17, 128.05, 128.03, 127.84, 126.99, 70.12, 58.60, 58.10, 56.89, 55.48, 43.45, 43.15, 38.55, 36.41, 36.05, 35.05, 33.17, 26.70, 26.47, 25.91, 25.63, 25.60, 25.54, 20.56, 16.03, 14.29.

[0161] ESI-MS (m / z): [M+Na] calculated for C 46 H 64 N4O5S 822.4234, found: 822.458.

[0162] Example 15

[0163] Referring to the synthesis of Example 5, step 2 was replaced by N-Boc-γ-aminobutyric acid as the raw material, and step 3 was replaced by 13-docosaenoic acid as the raw material to synthesize the C22U1L3V molecule (the structure is shown below).

[0164]

[0165] 1 H NMR (600MHz, DMSO) δ8.98(s,1H),8.56(t,J=6.1Hz,1H),7.90(d,J=9.3Hz,1H),7.73(t,J=5.6Hz,1H),7.39(q,4H),5.36– 5.29(m,2H),5.13(d,J=3.5Hz,1H),4.54(d,J=9.3Hz,1H),4.43(d,2H),4.35(s,1H),4.22(dd,J=15.8,5.5Hz,1H),3.69– 3.61(m,2H),3.05–2.96(m,2H),2.44(s,3H),2.29–2.20(m,1H),2.15–2.09(m,1H),2.03(t,J=7.4Hz,3H),1.97(q,J=6.5 Hz,3H),1.93–1.87(m,1H),1.64–1.54(m,2H),1.50–1.42(m,2H),1.32–1.18(m,28H),0.94(s,9H),0.85(t,J=6.9Hz,3H). 13 C NMR(151MHz,DMSO)δ172.47,172.42,172.24,170.13,151.92,148.18,139.97,13 1.63,130.11,129.10,127.89,69.35,59.17,56.85,42.12,40.51,38.57,38.41, 35.92,35.72,33.01,31.75,29.55,29.49,29.43,29.33,29.29,29.16,29.04,27 .02,26.85,26.26,25.77,22.56,16.41,14.41.ESI-MS(m / z):[M+Na]calculated for C 48 H 77 N5O5S 858.565, found:858.553.

[0166] Example 16

[0167] Referring to the synthesis of Example 5, step 2 was replaced by N-Boc-5-aminopentanoic acid as the raw material to synthesize the C20U4L4V molecule (structure shown below).

[0168]

[0169] 1 H NMR (600MHz, CDCl3) δ8.68(s,1H),7.41–7.32(m,5H),6.39(d,J=8.7Hz,1H),5.80(t,J=5.9Hz,1H),5.44–5.30(m,8H),4.72(t,J=8.1Hz,1H),4.59–

[0170] 4.50(m,3H),4.34(dd,J=15.0,5.4Hz,1H),4.07(d,J=11.3Hz,1H),3.62(dd,J= 11.3,3.5Hz,1H),3.19(q,J=6.6Hz,2H),2.83–2.79(m,4H),2.51(s,3H),2.29–

[0171] 2.23(m,1H),2.21–2.12(m,5H),2.11–2.03(m,5H),1.72–1.57(m,5H),1.51–1.44 (m,2H),1.39–1.33(m,2H),1.32–1.24(m,5H),0.94(s,9H),0.88(t,J=6.8Hz,3H). 13 C NMR (151MHz, CDCl3) δ173.48,173.29,171.89,170.87,150.32,148.48,138.15,131.59,130.9 6,130.55,129.52,129.12,128.76,128.64,128.28,128.15,128.08,127.84,127.51,70.08,5 8.56,57.62,56.87,43.22,38.74,36.18,36.10,35.52,35.08,31.52,29.32,28.84,27.23,26 .70,26.43,25.65,25.64,25.57,22.58,22.51,16.07,14.09.ESI-MS(m / z):[M+Na]calculated for C 47 H 68 N4O5S

[0172] 838.4910,found:838.501.

[0173] Embodiment 17

[0174] Referring to the synthesis of Example 5, step 2 was replaced by N-Boc-5-aminovaleric acid as the raw material, and step 3 was replaced by linoleic acid as the raw material to synthesize the C18U2L4V molecule (the structure is shown below).

[0175]

[0176] 1 H NMR (600 MHz, CDCl3) δ8.68 (s, 1H), 7.41 (t, J = 6.0 Hz, 1H), 7.35 (q, J = 8.3 Hz, 4H), 6.43 (d, J = 8.7 Hz, 1H), 5.89 (t, J = 5.9 Hz,1H),5.42–5.28(m,4H),4.72(t,J=8.1Hz,1H),4.58–4.49(m,3H),4.35(dd,J=15.0,5.4 Hz,1H),4.06(d,J=11.5 Hz,1H),4.00(s,1H),3.70(p,J=6.7 Hz,1H),3.62(dd,J=11.3,3.6 Hz,1H),3.22–3.11(m,3H),2.76(t,J=6.8 Hz,2H),2.51(s,3H),2.49–2.44(m,1H),2.28–2.23(m,1H),2.22–2.11(m,6H),2.08–2.00(m,4H),1.58(t,J=6.8 Hz,2H),1.38–1.24(m,16H),0.94(s,9H),0.89(t,J=6.9 Hz,3H). 13C NMR (151MHz, CDCl3) δ173.78,173.65,171.95,171.05,150.42,148.57,138.28,131.71,13 1.04,130.36,130.14,129.61,128.17,128.00,70.19,58.71,57.75,56.98,55.12,43.31,4 3.17,38.83,36.88,36.36,35.62,35.20,31.63,29.75,29.45,29.42,29.29,28.92,27.31 ,26.54,25.91,25.74,22.68,22.65,16.18,14.20,12.49.ESI-MS(m / z):[M+Na]calculated for C 45 H 69 N5O5S814.502, found:814.490.

[0177] Embodiment 18

[0178] Referring to the synthesis of Example 5, step 2 was replaced by N-Boc-5-aminovaleric acid as the raw material, and step 3 was replaced by linolenic acid as the raw material to synthesize the C18U3L4V molecule (the structure is shown below).

[0179]

[0180] 1H NMR (600MHz, CDCl3) δ8.68(s,1H),7.45–7.41(m,1H),7.35(q,4H),6.44(t,J=9.8Hz,1H),5.88(t,J=6.5Hz,1H),5.42–5.28(m,6 H),4.72(t,J=7.9Hz,1H),4.58–4.50(m,3H),4.34(dd,J=15.0,5.4Hz,1H),4.05(d,J=11.4Hz,2H),3.63(dd,J=11.2,3.6Hz,1H) ,3.19(q,J=6.6Hz,2H),2.83–2.77(m,4H),2.51(s,3H),2.49–2.44(m,1H),2.27–2.23(m,1H),2.21–2.11(m,5H),2.05(dt,J=23 .7,7.1Hz,4H),1.63–1.55(m,3H),1.52–1.44(m,2H),1.36–1.31(m,2H),1.30–1.27(m,6H),0.97(t,J=7.5Hz,3H),0.94(s,9H). 13 C NMR (151MHz, CDCl3) δ173.59,173.45,171.85,170.95,150.31,148.46,138.18,131.97,131 .60,130.93,130.24,129.50,128.30,128.23,128.05,127.74,127.10,70.05,58.61,57.61 ,56.86,43.19,40.98,38.71,36.77,36.26,35.51,35.15,29.61,29.30,29.16,28.84,27.2 1,26.43,25.79,25.62,25.53,22.54,20.55,16.06,14.29.ESI-MS(m / z):[M+Na]calculated for C 45 H 67 N5O5S 812.4761, found:812.473.

[0181] Embodiment 19

[0182] Referring to the synthesis of Example 5, step 2 was replaced by N-Boc-5-aminopentanoic acid as the raw material, and step 3 was replaced by cis-5,8,11,14,17-eicosapentaenoic acid as the raw material to synthesize the C20U5L4V molecule (structure shown below).

[0183]

[0184] 1 H NMR (600MHz, CDCl3) δ8.68(s,1H),7.42(t,J=6.0Hz,1H),7.35(q,J=8.4Hz,4H),6.44(d,J=8.8Hz,1H),5.85(t,J=5.9H z,1H),5.55–5.17(m,10H),4.71(t,J=8.1Hz,1H),4.59–4.49(m,4H),4.34(dd,J=15.0,5.3Hz,1H),4.06(d,J=11.8Hz,1 H),3.63(dd,J=11.2,3.6Hz,1H),3.19(q,J=6.6Hz,2H),2.84–2.76(m,4H),2.51(s,3H),2.49–2.44(m,1H),2.25(p,J= 7.2Hz,2H),2.21–2.12(m,5H),2.11–2.03(m,4H),1.72–1.55(m,5H),1.47(dq,J=14.0,6.7Hz,2H),0.99–0.93(m,12H). 13 CNMR(151MHz,CDCl3)δ173.48,173.31,171.84,170.94,150.34,148.45,138.17,132.07,131 .64,131.60,130.93,129.50,129.14,128.72,128.61,128.31,128.20,128.06,127.85,127. 00,70.07,58.61,57.61,56.88,43.20,40.96,38.75,36.26,36.09,35.51,35.13,28.85,26. 70,26.43,25.64,25.57,25.55,22.54,20.57,16.06,14.29.ESI-MS(m / z):[M+Na]calculated for C 45 H 67 N5O5S852.4500.,found:852.508.

[0185] Embodiment 20

[0186] Referring to the synthesis of Example 5, step 2 was replaced by N-Boc-5-aminopentanoic acid as the raw material, and step 3 was replaced by 13-docosaenoic acid as the raw material to synthesize the C22U1L4V molecule (the structure is shown below).

[0187]

[0188] 1 H NMR (600MHz, CDCl3) δ8.68(s,1H),7.39(t,J=6.0Hz,1H),7.35(q,J=8.3Hz,4H),6.40(d,J=8.8Hz,1H),5.81(t,J=5.9Hz, 1H),5.34(t,2H),4.71(t,J=8.1Hz,1H),4.58–4.49(m,3H),4.34(dd,J=15.0,5.3Hz,1H),4.07(d,J=11.5Hz,1H),3.61(dd ,J=11.3,3.6Hz,1H),3.19(q,J=6.6Hz,2H),2.51(s,3H),2.27–2.23(m,1H),2.21–2.10(m,4H),2.00(q,J=6.6Hz,4H),1. 64(dt,J=14.4,7.3Hz,1H),1.62–1.53(m,3H),1.51–1.39(m,3H),1.33–1.22(m,28H),0.93(s,9H),0.87(t,J=6.9Hz,3H). 13 C NMR (151MHz, CDCl3) δ173.68,173.56,171.90,170.88,150.36,148.38,138.19,131.66,130.90,12 9.93,129.88,129.51,128.09,70.09,58.56,57.65,56.88,43.22,38.70,36.81,36.17,35.51,35.0 5,32.62,31.91,29.80,29.78,29.72,29.69,29.66,29.59,29.55,29.53,29.50,29.41,29.37,29.3 5,29.33,28.82,27.23,26.43,25.81,22.69,22.51,16.03,14.13.ESI-MS(m / z):[M+Na]calculated for C 49 H 79 N5O5S 872.580, found:872.567.

[0189] Embodiment 21

[0190] Referring to the synthesis of Example 5, (2-aminoethoxy)acetic acid was used as the raw material in step 2 to synthesize the C20U4L4OV molecule (the structure is shown below).

[0191]

[0192] 1 H NMR (600MHz, CDCl3) δ8.68(s,1H),7.35(q,4H),7.13(d,J=8.8Hz,1H),6.18(t,1H),5.44–5.29(m,8H),4.72(t,J=7.9Hz, 1H),4.57–4.50(m,3H),4.37(dd,J=15.0,5.4Hz,1H),4.08–3.98(m,2H),3.89(d,J=15.5Hz,1H),3.69–3.61(m,2H),3.56– 3.51(m,1H),3.50–3.39(m,2H),3.34(s,1H),2.83–2.79(m,4H),2.52(s,3H),2.20(t,2H),2.16–2.11(m,1H),2.11–2.02 (m,4H),1.86(s,2H),1.70(p,J=7.0Hz,2H),1.36(q,J=7.3Hz,2H),1.32–1.25(m,5H),0.95(s,9H),0.88(t,J=6.9Hz,3H). 13 C NMR (151MHz, CDCl3) δ173.32,171.55,170.58,170.03,150.35,148.53,138.01,131.51,13 1.11,130.56,129.56,129.11,128.80,128.66,128.32,128.14,127.83,127.51,70.82,70 .18,70.13,58.53,57.04,56.83,43.28,39.16,35.93,35.87,35.14,31.52,29.33,27.23, 26.70,26.41,25.65,25.64,25.47,22.58,16.08,14.10.ESI-MS(m / z):[M+Na]calculated forC 46 H 67 N5O6S 840.4710, found:840.471.

[0193] Embodiment 22

[0194] Referring to the synthesis of Example 5, step 2 was replaced by (2-aminoethoxy)acetic acid as the raw material, and step 3 was replaced by linoleic acid as the raw material to synthesize the C18U2L4V molecule (the structure is shown below).

[0195]

[0196] 1 1H NMR (600 MHz, CDCl3) δ 8.68 (s, 1H), 7.45 (q, J = 5.8 Hz, 1H), 7.38–7.28 (m, 4H), 7.18 (d, J = 9.1 Hz, 1H), 6.52 (dd, J = 20.5, 8.9 Hz, 1H), 5.42–5.27 (m, 1H), 4.70 (t, J = 7.9 Hz, 1H), 4.56 (d, J = 9.1 Hz, 1H), 4.54–4.46 (m, 2H), 4.39 (dd, J = 14.9, 5.6 Hz, 1H), 4.00–3.93 (m, 2H), 3.88 (d, J = 15.5 Hz, 1H), 3.68 (dd, J = 11.1, 3.9 Hz, 1H), 3.66–3.61 (m, 1H), 3.55–3.44 (m, 2H), 3.41–3.35 (m, 1H), 2.75 (q, J = 5.5 Hz, 2H), 2.51 (s, 3H), 2.45–2.38 (m, 1H), 2.22–2.12 (m, 3H), 2.04 (q, J = 7.3 Hz, 4H), 1.42 (m, 3H), 1.36–1.24 (m, 14H), 0.96 (s, 9H), 0.88 (t, J = 7.0 Hz, 3H). 13 13C NMR (151 MHz, CDCl3) δ 173.86, 173.84, 171.18, 171.04, 169.84, 150.37, 148.41, 138.17, 138.15, 131.56, 130.92, 130.23, 129.98, 129.46, 128.06, 128.00, 127.87, 70.69, 70.03, 69.98, 58.87, 56.90, 56.85, 55.37, 43.13, 39.05, 36.51, 35.58, 31.49, 29.64, 29.35, 29.32, 27.19, 26.39, 25.73, 25.62, 22.56, 18.56, 17.18, 16.05, 14.08, 12.54. ESI-MS (m / z): [M+Na] calculated for C 44 H 67 N5O6S 816.4710, found: 816.471.

[0197] Example 23

[0198] Referring to the synthesis of Example 5, step 2 was replaced by (2-aminoethoxy)acetic acid as the raw material, and step 3 was replaced by linolenic acid as the raw material to synthesize the C18U3L4OV molecule (the structure is shown below).

[0199]

[0200] 1 H NMR (600 MHz, CDCl3) δ8.65 (s, 1H), 7.39 (d, J = 6.0 Hz, 1H), 7.32 (q, J = 7.8 Hz, 4H), 7.14 (d, J = 9.0 Hz,1H),6.47–6.39(m,1H),5.40–5.25(m,6H),4.67(m,1H),4.53(d,J=9.1 Hz,1H),4.51–4.46(m,2H),4.36(dd,J=15.0,5.6 Hz,1H),3.97–3.92(m,2H),3.86(d,J=15.5Hz,1H),3.66–3.59(m,2H),3.53–3.41(m,2H),3.38–3.33(m,1H),3.17–3.13(m,1H),2.77(q,J=5.6 Hz,3H),2.48(s,3H),2.43–2.37(m,1H),2.15(t,J=7.6 Hz,2H),2.06–1.98(m,4H),1.41–1.36(m,4H),1.32–1.23(m,8H),0.96–0.90(m,12H). 13 C NMR(151 MHz, CDCl3)δ173.84,171.22,170.99,169.88,150.36,148.43,138.14,131.98,131.56,130.92 ,130.21,129.47,128.30,128.19,128.02,127.72,127.09,70.69,70.07,70.00,58.84,56.93, 56.84,55.46,43.15,39.07,36.52,35.53,31.50,29.62,29.35,29.33,29.17,27.21,26.40,25 .73,25.61,25.52,20.54,18.56,17.16,16.05,14.29,12.56.ESI-MS(m / z):[M+Na]calculated forC 44 H 65 N5O6S 814.4553, found:814.450.

[0201] Embodiment 24

[0202] Referring to the synthesis of Example 5, step 2 was replaced with (2-aminoethoxy)acetic acid as the raw material, and step 3 was replaced with cis-5,8,11,14,17-eicosapentaenoic acid as the raw material to synthesize the C20U5L4OV molecule (structure shown below).

[0203]

[0204] 1 H NMR (600MHz, CDCl3) δ8.65(s,1H),7.38(t,J=6.0Hz,1H),7.32(q,J=8.3Hz,4H),7.14(d,J=9.1Hz,1H),6.42(t,J=5.8Hz,1H),5 .43–5.22(m,10H),4.67(t,J=7.9Hz,1H),4.55–4.45(m,3H),4.36(dd,J=15.1,5.7Hz,1H),4.09(s,1H),3.97–3.90(m,2H),3.86 (d,J=15.5Hz,1H),3.71–3.57(m,3H),3.52–3.42(m,2H),3.40–3.32(m,1H),3.15(q,J=7.5Hz,1H),2.76–2.74(m,2H),2.48(s, 3H),2.42–2.36(m,1H),2.17(t,2H),2.15–2.10(m,1H),2.04(m,4H),1.68–1.62(m,2H),1.43–1.37(m,4H),0.96–0.92(m,12H). 13 C NMR (151MHz, CDCl3) δ173.52,171.19,171.02,169.86,150.38,148.42,138.14,132.04,131.56,130 .92,129.47,129.10,128.72,128.59,128.31,128.21,128.18,128.04,128.02,127.83,126.99,70. 65,70.05,70.00,58.85,56.94,56.83,55.42,43.38,43.14,39.08,36.48,35.84,35.53,26.69,26. 40,25.62,25.53,25.52,20.53,18.56,17.16,16.02,14.30,12.55.ESI-MS(m / z):[M+Na]calculated for C46 H 65 N5O6S 838.4553, found:838.453.

[0205] Embodiment 25

[0206] Referring to the synthesis of Example 5, step 2 was replaced by N-Boc-6-aminohexanoic acid as the raw material to synthesize the C20U4L5V molecule (structure shown below).

[0207]

[0208] 1 H NMR (600MHz, CDCl3) δ8.68(s,1H),7.44(t,J=6.0Hz,1H),7.38–7.33(m,4H),6.30(d,J=8.9Hz,1H),5.74(t,J=5.8Hz,1H),5.43– 5.30(m,8H),4.72(t,J=8.1Hz,1H),4.58–4.49(m,3H),4.35(dd,J=15.0,5.4Hz,1H),4.05(d,J=11.5Hz,1H),3.94(s,1H),3.62( dd,J=11.2,3.6Hz,1H),3.19(q,J=6.4Hz,2H),2.83–2.79(m,4H),2.51(s,3H),2.49–2.44(m,1H),2.24–2.11(m,6H),2.12–2.02 (m,4H),1.68(p,J=7.5Hz,2H),1.64–1.55(m,2H),1.46(p,J=7.4Hz,2H),1.40–1.23(m,9H),0.94(s,9H),0.88(t,J=7.0Hz,3H). 13CNMR (151MHz, CDCl3) δ173.51,173.02,171.82,170.95,150.32,148.46,138.17,131.60,130. 93,130.54,129.50,129.13,128.74,128.63,128.27,128.14,128.06,127.83,127.51,70.00, 58.63,57.48,56.84,43.19,39.25,36.23,36.11,35.11,31.51,29.32,29.30,27.22,26.69,2 6.42,26.21,25.65,25.63,25.58,25.09,22.57,16.06,14.09.ESI-MS(m / z):[M+K]calculated for C 48 H 70 N4O5S 852.4704, found:852.508.

[0209] Embodiment 26

[0210] Referring to the synthesis of Example 5, step 2 was replaced by N-Boc-6-aminocaproic acid as the raw material, and step 3 was replaced by linoleic acid as the raw material to synthesize the C18U2L5V molecule (the structure is shown below).

[0211]

[0212] 1H NMR (600MHz, CDCl3) δ8.64(s,1H),7.48(t,J=7.2Hz,1H),7.31(q,J=2.8Hz,4H),6.45–6.39(m,1H),6.00(p,J=5.6Hz,1H),5. 38–5.26(m,4H),4.67(t,J=7.2Hz,1H),4.51–4.45(m,2H),4.33(dd,J=15.1,5.5Hz,1H),4.28–4.22(m,1H),3.97(d,J=11.5Hz ,1H),3.62(dd,J=11.1,3.8Hz,1H),3.15(q,J=6.6Hz,2H),2.73(t,J=6.9Hz,2H),2.47(s,3H),2.40–2.32(m,1H),2.17–2.06 (m,4H),2.00(p,J=6.8Hz,4H),1.59–1.50(m,4H),1.40–1.36(m,4H),1.30–1.22(m,14H),0.92(s,9H),0.85(t,J=7.0Hz,3H). 13 C NMR (151MHz, CDCl3) δ173.49,173.46,171.65,171.19,150.34,148.37,138.25,131.64,130.81,130 .22,130.00,129.43,128.04,127.97,127.87,69.96,58.82,57.51,56.82,55.36,53.47,43.35,43. 10,39.22,36.74,36.55,36.06,35.28,31.50,29.63,29.32,29.30,29.19,29.17,27.19,26.43,26. 24,25.85,25.62,25.12,22.56,18.55,17.12,16.05,14.08,12.62.ESI-MS(m / z):[M+K]calculated for C 46 H 70 N4O5S 828.4704, found:828.506.

[0213] Embodiment 27

[0214] Referring to the synthesis of Example 5, step 2 was replaced by N-Boc-6-aminocaproic acid as the raw material, and step 3 was replaced by linolenic acid as the raw material to synthesize the C18U2L5V molecule (the structure is shown below).

[0215]

[0216] 1 1H NMR (600 MHz, CDCl3) δ 8.68 (s, 1H), 7.46 (t, J = 6.0 Hz, 1H), 7.37–7.33 (m, 4H), 6.43 (d, J = 8.7 Hz, 2H), 6.16 (q, J = 5.2 Hz, 1H), 5.43–5.27 (m, 6H), 4.69 (t, J = 8.1 Hz, 1H), 4.54–4.48 (m, 3H), 4.37 (dd, J = 15.1, 5.6 Hz, 1H), 4.00 (d, J = 11.2 Hz, 1H), 3.75–3.63 (m, 4H), 3.23–3.12 (m, 6H), 2.80 (q, J = 5.3 Hz, 4H), 2.50 (s, 3H), 2.41–2.35 (m, 1H), 2.25–2.11 (m, 5H), 2.11–2.00 (m, 4H), 1.62–1.53 (m, 4H), 1.47 (q, J = 7.4 Hz, 2H), 1.34–1.25 (m, 12H), 1.02–0.92 (m, 12H). 13 13C NMR (151 MHz, CDCl3) δ 173.74, 173.62, 171.64, 171.29, 150.37, 148.33, 138.23, 131.96, 131.68, 130.76, 130.23, 129.41, 128.29, 128.22, 127.94, 127.71, 127.08, 70.01, 58.88, 57.64, 56.76, 55.58, 43.52, 43.07, 39.28, 36.72, 36.63, 36.04, 35.19, 31.49, 29.62, 29.59, 29.30, 29.25, 29.16, 29.02, 27.20, 26.42, 26.19, 25.92, 25.62, 25.60, 25.51, 25.15, 22.55, 20.54, 18.47, 16.98, 16.05, 14.28, 12.71. ESI-MS (m / z): [M+K] calculated for C 46 H 68 N4O5S 826.4547, found: 826.489.

[0217] Example 28

[0218] Referring to the synthesis of Example 5, step 2 was replaced with N-Boc-6-aminohexanoic acid as the raw material, and step 3 was replaced with cis-5,8,11,14,17-eicosapentaenoic acid as the raw material to synthesize the C20U5L5V molecule (structure shown below).

[0219]

[0220] 1 H NMR (600 MHz, CDCl3) δ8.68 (s, 1H), 7.47 (t, J = 6.0 Hz, 1H), 7.38–7.32 (m, 4H), 6.41 (d, J = 9.2 Hz, 1H), 6.01 (t, J = 5.9 Hz,1H),5.43–5.28(m,10H),4.70(t,J=8.0Hz,1H),4.56–4.49(m,3H),4.36(dd,J=15.1,5.5 Hz,1H),4.01(d,J=11.2 Hz,1H),3.75–3.63(m,3H),3.18(p,J=6.6 Hz,4H),2.87–2.76(m,8H),2.50(s,3H),2.43–2.37(m,1H),2.25–2.11(m,6H),2.08(q,J=6.8 Hz,4H),1.66(p,J=7.5 Hz,2H),1.59(p,J=7.6 Hz,2H),1.33–1.24(m,2H),1.02–0.92(m,12H). 13 C NMR(151 MHz, CDCl3)δ173.56,173.28,171.67,171.19,150.37,148.36,138.23,132.05,131.66,130.80,129.4 4,129.11,128.69,128.58,128.28,128.19,128.18,128.05,127.98,127.84,126.98,70.00,58.82,57. 57,56.80,55.51,53.47,43.47,43.11,39.27,36.52,36.09,36.06,35.21,29.14,26.68,26.43,26.21, 25.67,25.62,25.53,25.12,20.55,18.52,17.06,16.05,14.28,12.67.ESI-MS(m / z):[M+K]calculated for C 48 H 68 N4O5S 850.4547, found:850.488.

[0221] Embodiment 29

[0222] CCK8 cell proliferation assay: PANC-1 and MIAPACA2 cells were incubated with the above compounds at different concentrations for 72 h. The CCK8 cell proliferation activity assay showed that C18U2L3V had the highest pancreatic cancer killing efficiency (see Figure 2-1 ), and through the IC 50 The area under the region was integrated and it was found that pancreatic cancer was highly sensitive to drugs of C20U4LV, C20U4L1V, C18U2L3V, and C18U2L4OV (see Figure 2-2 , Figure 2-3 ).

[0223] Embodiment 30

[0224] Combination of the two drugs: Cell proliferation assay-plate clone formation experiment was used to detect the effect of the combination of the two drugs on the proliferation ability of pancreatic tumor cells. Different concentrations of C20U4LV (1μm, 3μm, 5μm) and MOF-Fe@PEI (0.3μg / ml, 1μg / ml, 3μg / ml) were used alone and in combination. It was found that when the two drugs were used in combination, they had a strong synergistic effect (see Figure 3 ). In the human pancreatic cancer cell line PANC-1, compared with the control group without drug addition, the cell clone percentage after combined treatment of 1 μm C20U4LV and 3 μg / ml MOF-Fe@PEI was 10.3%, which was much lower than the single application of 1 μm C20U4LV (cell clone percentage: 89.13%) and the single application of 3 μg / ml MOF-Fe@PEI (cell clone percentage: 32.6%).

[0225] Embodiment 31

[0226] Western blotting (WB) experiment: Based on the experimental results of Example 29, the cell killing effect and drug sensitivity of the above compounds on PANC-1 and MIAPACA2 cells were comprehensively considered, and four compounds (C20U4LV, C20U4L1V, C18U2L3V, C18U2L4OV) were selected for ferritin degradation experimental verification. Due to the use of MOF-Fe@PROTAC@PEI dosage form, MOF-Fe@PEI (10 μg / ml) was added at the same time as the drug (10 μm / ml), and after incubation with PANC-1 cells for 48 hours, WB experiments were performed. Western blotting was used to analyze proteins, cells were lysed using lysis buffer, and protein concentration was determined using a BCA kit. 20 μg of protein was taken for immunoblotting analysis, and the degradation efficiency of ferritin was characterized using FTH1 (1:3000, (A1144), ABclonal), β-Actin (1:4000, (AC026), ABclonal), and β-Actin (1:4000, (AC026), ABclonal). The experimental results show that MOF-Fe can significantly upregulate the expression of ferritin by delivering iron ions to pancreatic cancer, while C18U2L3V and C20U4LV can effectively degrade the expression of ferritin (see Figure 4 ).

[0227] Embodiment 32

[0228] On the other hand, in order to further prove the mechanism of this type of PROTAC molecule, VHL ligand drug ((2S,4R)-1-((S)-2-amino-3,3-dimethylbutyryl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride) was used to inhibit the performance of PROTAC (taking C20U4LV as an example). Western blotting (WB) experiments showed that the addition of VHL-ligand can indeed effectively inhibit the degradation of ferritin by this molecule, further confirming that this type of PROTAC molecule binds through E3 ubiquitin ligase, making ferritin highly ubiquitinated and ultimately degraded through the proteasome pathway (see Figure 5 ).

[0229] Embodiment 33

[0230] The effect of obtaining the compound of formula I by using MOF-Fe@PEI drug-loaded PROTAC: In order to better analyze the anti-cancer efficiency of the compound of formula I in vivo and overcome the drug disadvantages of PROTAC molecules, by using MOF-Fe@PEI drug delivery strategy, MOF-Fe@PEI nanomedicine was used to improve the small molecule targeting and drug delivery efficiency of PROTAC, and the molecule was observed to have good stability by electron microscopy (as shown in the figure, taking MOF-Fe@PEI@C20U4LV as an example).

[0231] The preparation of the compound of formula I obtained by MOF-Fe@PEI drug-loaded PROTAC includes the following steps: 2-aminoterephthalic acid (NH2-BDC) (200 mg) and iron (III) chloride hexahydrate (FeCl3.6H2O) (600 mg) are added to a reactor at 110°C for 48 hours. After drying in an oven at 100°C, 100 mg of MOF-Fe is added to PROTAC (10 mg), ultrasonically dispersed, and incubated at room temperature for 24 hours. The above nanoparticles are washed by centrifugation, cationic polyimine is added and incubated for 24 hours, the precipitate is collected by centrifugation, and resuspended.

[0232] Embodiment 34

[0233] Definitions and explanations of terms:

[0234] Unless otherwise specified, the definitions of groups and terms recorded in the specification and claims of this application, including their definitions as examples, exemplary definitions, preferred definitions, definitions recorded in tables, definitions of specific compounds in examples, etc., can be arbitrarily combined and combined with each other. The group definitions and compound structures after such combination and combination shall fall within the scope recorded in the specification of this application.

[0235] Unless otherwise specified, the numerical ranges recorded in this specification and claims are equivalent to recording at least each specific integer value therein. For example, the numerical range "1-10" is equivalent to recording each integer value in the numerical range "1-10", namely 1, 2, 3, 4, 5, 6, 7, 8, 9, 10. It should be understood that in the one, two or more used herein when describing substituents, "more" should refer to an integer ≥ 3, such as 3, 4, 5, 6, 7, 8, 9 or 10.

[0236] The term "C 1-50 The term "alkyl chain" refers to a straight or branched chain alkyl group having 1 to 50 carbon atoms.

[0237] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. Ferritin-targeted ferroptosis-inducing nanoparticle formulation, characterized in that: It contains a MOF-Fe@PROTAC@PEI complex, wherein the MOF-Fe@PROTAC@PEI complex comprises a compound of general formula I and MOF-Fe nanoparticles, wherein the MOF-Fe nanoparticles are loaded with the compound of general formula I through the internal pores to form MOF-Fe@PROTAC, and the surface of the MOF-Fe@PROTAC is coated with cationic polyimine to form a MOF-Fe@PROTAC@PEI complex.

2. The ferroptosis-inducing nano dosage form targeting ferritin according to claim 1, characterized in that: The cationic polyimine includes one or more of polyetherimide PEI and polyoxypolyamine ODA.

3. The ferroptosis-inducing nano dosage form targeting ferritin according to claim 1, characterized in that: The structure of the compound of general formula I is shown below: in, represents the ligand of E3 ubiquitin ligase; The -L- represents a linking group, which is selected from C 1-50 An alkyl chain, wherein the heteroatom is selected from O, S, and N; Said It represents various saturated or unsaturated long alkyl chains, which are produced by the reaction of saturated or unsaturated fatty acids and their acyl halides, anhydride derivatives and amino groups; the saturated or unsaturated fatty acid is selected from any one of palmitic acid, oleic acid, linoleic acid, linolenic acid, arachidonic acid and eicosapentaenoic acid.

4. The ferroptosis-inducing nano dosage form targeting ferritin according to claim 1, characterized in that: The compound of general formula I is further selected from the following formula II, formula III, and formula IV: In the general formula II, -L- represents a linking group, Represents various saturated or unsaturated long alkyl chains, which are produced by the reaction of saturated or unsaturated fatty acids and their acyl halides and anhydride derivatives with amino groups; In the general formula III, represents various saturated or unsaturated long alkyl chains, which are produced by the reaction of saturated or unsaturated fatty acids and their acyl halides, anhydride derivatives with amino groups, and n is selected from 1-100; In the general formula IV, Represents various saturated or unsaturated long alkyl chains, which are produced by the reaction of saturated or unsaturated fatty acids and their acyl halides, anhydride derivatives with amino groups, and n is selected from 1-100.

5. A method for preparing a ferroptosis-inducing nano dosage form targeting ferritin, characterized in that: include: Step 1, prepare a compound of general formula I, the structure of the compound of general formula I is shown below: in, represents the ligand of E3 ubiquitin ligase; The -L- represents a linking group, which is selected from C 1-50 An alkyl chain, wherein the heteroatom is selected from O, S, and N; Said Represents various saturated or unsaturated long alkyl chains, which are produced by the reaction of saturated or unsaturated fatty acids and their acyl halides and anhydride derivatives with amino groups; Step 2, preparing MOF-Fe nanoparticles; Step 3, prepare a MOF-Fe@PROTAC@PEI complex, load the compound of general formula I through the internal pores of the MOF-Fe nanoparticles to form MOF-Fe@PROTAC, and then wrap the MOF-Fe@PROTAC surface with cationic polyimine to form a MOF-Fe@PROTAC@PEI complex, and further prepare an ferroptosis-inducing nanoformulation targeting ferritin by preparing an ferroptosis inducer.

6. The method for preparing the ferritin-targeted ferroptosis-inducing nano dosage form according to claim 5, characterized in that: The preparation steps of the compound of general formula I include: 1) VHL-Ligand Step 11, synthesis of c, d type molecules: The above compound a was dissolved in organic reagent A, 1.2eq of Boc-protected amino acid molecules of different lengths were selected, condensation reagent A was added, nitrogen was protected, and the reaction was carried out at room temperature for 2-4 hours, and the crude product was extracted with 5% sodium carbonate solution and organic reagent B, and the target product c was purified by silica gel column; the synthesis of molecule d was the same as that of molecule c; Step 12, synthesis of e, f type molecules: Molecule c was dissolved in dichloromethane, 3 eq of hydrochloric acid (4M)-1,4-dioxane was added, and the mixture was reacted at room temperature for 30 minutes. The crude product e was obtained after rotary evaporation. The synthesis of molecule e was the same as that of molecule f. Step 13, synthesis of OALnV, OALnOV molecules: Dissolve compound e in organic reagent A, select different fatty acids or their anhydrides, 1 eq of acyl halide derivatives, add 2 eq of condensation reagent C and the alkali solution used in combination, protect with nitrogen, react at room temperature overnight, extract with 5% sodium carbonate solution and organic reagent B to obtain a crude reaction product, and purify with a silica gel column to obtain the target product OALnV; the synthesis of molecule OALnV is the same as that of molecule OALnOV.

7. The method for preparing the ferritin-targeted ferroptosis-inducing nano dosage form according to claim 6, characterized in that: The organic reagent A is selected from dimethyl sulfoxide, N,N-dimethylformamide, acetonitrile, and dichloromethane; the organic reagent B is selected from ethyl acetate and dichloromethane; the condensation reagent C is selected from O-(7-azabenzotriazole-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate HATU, N,N'-carbonyldiimidazole CDI, and N,N,N',N'-tetramethylchloroformamidine hexafluorophosphate TCFH.

8. The method for preparing the ferritin-targeted ferroptosis-inducing nano dosage form according to claim 5, characterized in that: The MOF-Fe nanoparticle preparation step comprises the following steps: Step 21, adding 2-aminoterephthalic acid NH2-BDC and iron (III) chloride hexahydrate FeCl3.6H2O into a reaction kettle, 110°C, and reacting for 48h; Step 22: After drying in an oven at 100°C, PROTAC was added, ultrasonically dispersed, and incubated at room temperature for 24 h; Step 23: The nanoparticles are washed by centrifugation, cationic polyimine is added and incubated for 24 hours, the precipitate is collected by centrifugation, and the precipitate is resuspended.

9. Use of the compound of general formula I or the MOF-Fe@PROTAC@PEI composite nanomedicine according to any one of claims 1 to 4 in the preparation of anti-tumor drugs.

10. Use of the compound of general formula I or the MOF-Fe@PROTAC@PEI composite nanomedicine according to any one of claims 1 to 4 in the preparation of ferroptosis inducers.

Citation Information

Patent Citations

  • Ferroptosis inducer based on PROTAC design

    CN115109047A

  • Albumin nanoparticles entrapped with ferroptosis-related drugs as well as preparation method and application of albumin nanoparticles

    CN117771242A